Abfero Pharmaceuticals Announces Initiation of Phase 1 Study for Lead Iron Chelator
UF startup AbFero Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO).
Plasma Oxalate and Kidney Function Are Correlated in Patients With Primary Hyperoxaluria With Maintained Kidney Function – Data From Three Placebo-Controlled Studies Published
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.
AbFero Pharmaceuticals Announces Funding From Cure Parkinson’s for Lead Compound SP-420
AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, announced the award of a grant from Cure Parkinson's for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson's disease (PD).
DNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors Published in Clinical Cancer Research
UF startup DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced preclinical data evaluating the use of DNX-2401 against the pediatric brain malignancies atypical teratoid/rhabdoid tumor (AT/RT) and primitive neuroectodermal tumors (PNETs) was published in Clinical Cancer Research.
ASABE names AGROVIEW winner of a 2021 AE50 award
The American Society of Agricultural and Biological Engineers (ASABE) has named AGROVIEW winner of a 2021 AE50 award.
Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies
UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, announced that it has signed an agreement with Charles River Laboratories for preclinical studies of AP-188 (N,N-Dimethyltryptamine or DMT) for the company’s stroke clinical research program.
Tampa Company Developing Cancer Vaccines Could Receive Grant To Research Cervical Cancer Vaccine
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a Tampa-based company that has been researching and developing a vaccine for certain types of skin cancers, could be soon receiving a grant to begin research on a cervical cancer treatment for underprivileged women.
SARS-CoV-2 Spike Protein Licensed by Oragenics From the NIH Demonstrates Protective Immunity in Mice
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.
Purina Announces 2021 Pet Care Innovation Prize Winners
UF startup Structured Monitoring Products' VetGuardian was among the five winners. VetGuardian is a zero-touch remote telemonitor for veterinarians that continuously gathers a patient's vital signs without wires or physical contact.
Skin Cancer Vaccine Developed by Tampa Company Enters Phase 1 of Clinical Trial
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc. completed its first-in-human phase one trial in cutaneous melanoma at Moffitt Cancer Center within the past year and has now moved into studying patients in earlier stages of skin cancers.
